More than sixty years after Calvin Stevens first synthesized ketamine in the laboratories of Parke-Davis—originally intended as a safer anesthetic alternative—the molecule has completed a remarkable evolution. It has migrated from the surgical theater to the forefront of psychiatric medicine, where its potent S-enantiomer, esketamine, has emerged as a clinical blockbuster. Marketed by Johnson & Johnson as Spravato, the nasal spray is currently carving a dominant, albeit scrutinized, path through the treatment-resistant depression (TRD) landscape.
With annual revenues reaching approximately $1.7 billion in the previous year and Wall Street analysts projecting a surge toward $2.3 billion by 2026, Johnson & Johnson is moving aggressively to cement its market position. The company’s latest maneuver involves a strategic focus on remission data, a metric often neglected in psychiatric literature, recently showcased at the Psych Congress Elevate.
The Evolution of a Psychiatric Paradigm: A Chronology
The history of esketamine is one of transformation. For decades, ketamine remained a niche anesthetic, prized for its ability to maintain respiratory drive. However, its off-label use in psychiatry began to gain traction as researchers observed its rapid-acting antidepressant effects.
- March 2019: The FDA granted approval for Spravato as an intranasal add-on therapy for TRD, marking the first time a ketamine-derivative had cleared the regulatory hurdles for depression.
- January 2025: In a significant regulatory win, the FDA expanded Spravato’s label, clearing it as the first and only monotherapy for adults suffering from TRD, eliminating the requirement that it be used solely as an adjunct to traditional antidepressants.
- 2025–2026: As the clinical community grapples with the transition from traditional oral antidepressants to interventional psychiatry, J&J has focused its marketing and scientific communications on "remission"—a state of near-total symptom resolution—rather than mere clinical improvement.
The Magnitude of the Unmet Need
The potential market for Spravato is as vast as it is underserved. According to the National Institute of Mental Health (NIMH), an estimated 21 million U.S. adults experienced at least one major depressive episode in 2021, accounting for roughly 8.3% of the adult population.
Of the 8.9 million U.S. adults receiving pharmacological treatment for major depression, clinical data suggests that approximately one-third—roughly 2.8 million individuals—fail to respond to two or more trials of standard oral antidepressants. This failure to achieve remission is the hallmark of treatment-resistant depression.
"There are millions upon millions of patients, some of them your friends and mine, some of them your family members, who are being treated for depression and are simply not in remission," says Dr. Rakesh Jain, a clinical professor of psychiatry at Texas Tech University School of Medicine and lead author of the recent analysis. Dr. Jain contends that the psychiatric community has become overly tolerant of "response" (a reduction in symptoms) when it should be demanding "remission" (the absence of clinical symptoms).
The Data Gap: Why Remission Remains Elusive
In clinical trials for psychiatric drugs, "remission" is often a missing metric. Dr. Jain points to the seminal STAR*D trial—the largest real-world study of depression treatment—to illustrate the problem. The study revealed a sobering reality: as patients cycle through failed antidepressant treatments, the probability of achieving remission drops precipitously. After the first line of treatment, remission rates hover near 28%; by the third step, after two prior failures, that rate collapses to roughly 13.7%.
The recent J&J-backed analysis presented by Dr. Jain seeks to change this narrative by aggregating data from six key clinical trials, including the monotherapy trial (TRD4005), the landmark TRANSFORM-2 study, and the active-comparator trial ESCAPE-TRD. The analysis measures success against the Montgomery-Åsberg Depression Rating Scale (MADRS), a 10-item clinician-rated instrument.
Key Findings from the Compiled Data
The data compilation reports impressive figures for Spravato compared to placebos:
- Short-term Efficacy: In the TRANSFORM-2 study, remission (defined as a MADRS score ≤10) at week 4 reached 42.6% for the Spravato-plus-antidepressant group, compared to 24.0% for the placebo-plus-antidepressant cohort.
- Long-term Durability: In open-label extensions, which tracked patients for as long as 5.5 years, remission rates were reported at 49.3% at one year, 78.2% at two-and-a-half years, and 43.2% at the final follow-up.
However, the authors of the poster acknowledge that these findings are descriptive. They lack the rigorous structure of a formal meta-analysis, and the inherent differences in trial designs—ranging from double-blind studies to long-term open-label observations—limit direct statistical comparison.
The Debate Over Clinical Value
Despite the enthusiasm surrounding the data, the psychiatric community remains divided. The evidentiary threshold for Spravato is a point of ongoing contention among global health bodies.
The U.S. Department of Veterans Affairs (VA) and the Department of Defense (DoD) currently classify ketamine/esketamine as a "weak for" recommendation, citing low-quality evidence and concerns over the feasibility of the required monitoring. Internationally, the reception has been even cooler; in 2022, Britain’s National Institute for Health and Care Excellence (NICE) declined to recommend the drug for routine NHS use, citing insufficient evidence of long-term cost-effectiveness.
Furthermore, critics argue that the "add-on" benefit observed in trials is marginal. A recent systematic review published in the American Journal of Psychiatry by Fountoulakis et al. suggested that esketamine’s effect sizes during the initial 2–4 weeks are comparable to atypical antipsychotic augmentation—an older, cheaper, and more established practice.
Addressing the "Psychology" of the Clinician
Dr. Jain suggests that the primary barrier to broader adoption isn’t just the data—it is "clinician inertia." Psychiatry, he notes, is historically slow to adopt new, resource-intensive modalities.
Spravato’s administration requires a restricted Risk Evaluation and Mitigation Strategy (REMS) program. Because of the risk of dissociation, sedation, and potential abuse, every dose must be administered in a certified clinical setting, followed by at least two hours of mandatory observation. Patients are strictly prohibited from driving until the next day.
"There are multiple roadblocks, but I think one of the bigger ones is clinician hesitation and lack of knowledge," Dr. Jain asserts. By highlighting the remission rates, J&J is attempting to shift the clinical mindset from "managing depression" to "achieving remission," arguing that the complexity of the REMS program is a necessary trade-off for superior outcomes.
Implications for the Future
The expansion of Spravato’s label to include monotherapy status in 2025 has created a new gateway for patients who cannot tolerate traditional oral antidepressants. However, the path forward will likely involve a battle over the definition of "meaningful improvement."
As J&J continues to push for early adoption in the treatment sequence, the company faces the dual challenge of convincing a conservative medical establishment and navigating the skepticism of academic researchers. Whether the current push to prioritize remission will successfully overcome the logistical hurdles and cost-effectiveness concerns remains the central question for the future of the drug.
For now, the data presented at Psych Congress Elevate serves as a tactical rallying cry for clinicians to move beyond the status quo. If the industry and the medical community can reach a consensus on the value of these remission rates, Spravato may well become the standard-bearer for a new era of psychiatric intervention. Yet, as the critical literature reminds us, the journey from clinical trial efficacy to real-world clinical excellence is long, complex, and far from over.
About the Author
